Co-founded Kannalife Sciences, Inc. in 2010 and was principally responsible for the creation and execution of the Company’s business model, including the licensing of US Patent #6630507 from the National Institutes of Health for disease indications Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). In 2013, responsible for securing Series A financing for Neuropathix, Inc. (formerly, Kannalife Sciences, Inc.) and taking the company public in 2019 under the old ticker symbol KLFE. On November 6, 2020, Kannalife, Inc. changed its name to Neuropathix, Inc.Co-inventor of US Patent #9611213 “Novel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy”, and three other PCT / WIPO patents filed.From 1992 to 1994, was the lead investment banker for Xechem International, Inc. private placement offering and subsequent IPO to finance lead target drug candidate (generic paclitaxel)Joined Xechem International in December 2002 as V.P. of Business Development where principal responsibilities included consecutive EXIM Bank rounds of financing for the development and commercialization of Xechem’s drug Hemoxin (Nicosan), a phyto-pharmaceutical compound for the treatment of Sickle Cell disease.